Eric Liebler News Today

ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with...

GuruFocus Article or News written by GuruFocusNews and the topic is about:

NVNS reduces symptoms of PTSD by 31% in sham-controlled study...

GuruFocus Article or News written by GuruFocusNews and the topic is about:

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders April 26, 2021 08:00 ET | Source: electroCore, Inc. electroCore, Inc. Rockaway, New Jersey, UNITED STATES ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) --  -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

2  “gammaCore (nVNS) is the only treatment option, drug or device, that is currently available for the acute and preventive treatment of migraine in adolescents,” said Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “With their interest in technology and desire to avoid prescription drugs, gammaCore represents a unique treatment for adolescents with migraine. We would like to thank the Division of Neuromodulation and Physical Medicine Devices and their colleagues at...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to ... electroCoreFebruary 9, 2021 GMT ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major col...

Published: Feb 02, 2021 ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurologic...